Grace Therapeutics GRCE
NASDAQ GRCE
$1.75 -0.06 (-3.31%)
At close: Nov 16, 2026 · 4:00 PM EST

Grace Therapeutics (GRCE) Current Deferred Tax Assets (2020 - 2021)

Updated

Grace Therapeutics' Current Deferred Tax Assets came in at -$39.22 million for fiscal Q4 2021 (quarter ended Mar 31, 2021), compared with -$30.46 million a year earlier.

Analysis

Grace Therapeutics (GRCE) Current Deferred Tax Assets (2020 - 2021) Analysis & Trends

  • Going back by fiscal year, Current Deferred Tax Assets was -$30.46 million in FY2020.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,276.89 Bn 1,250.50 Bn 20.46 Bn
2 Johnson & Johnson 681.31 Bn 601.18 Bn 17.30 Bn
3 AbbVie 520.63 Bn 488.64 Bn 13.12 Bn
4 Merck 357.22 Bn 320.16 Bn 13.19 Bn
5 Novartis Ag 310.90 Bn 284.14 Bn -
6 Astrazeneca 285.12 Bn 258.77 Bn 13.26 Bn
7 Amgen 250.23 Bn 201.89 Bn 7.58 Bn
8 Gilead Sciences 207.56 Bn 182.67 Bn 6.73 Bn
9 Pfizer 164.42 Bn 111.77 Bn 12.56 Bn
10 Grace Therapeutics 35.10 Mn -35.61 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2021 -39.22 Mn
Mar 31, 2020 -30.46 Mn
API Access

Grace Therapeutics Current Deferred Tax Assets API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-tax-assets&ticker=GRCE&period=max&api_key=YOUR_API_KEY